Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

308.91
+0.28000.09%
Pre-market: 299.82-9.0900-2.94%08:08 EDT
Volume:120.36K
Turnover:37.06M
Market Cap:36.59B
PE:-185.82
High:309.68
Open:308.84
Low:306.35
Close:308.63
52wk High:330.63
52wk Low:170.99
Shares:118.45M
Float Shares:75.99M
Volume Ratio:0.65
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6624
EPS(LYR):-6.1240
ROE:-4.98%
ROA:-1.06%
PB:9.70
PE(LYR):-50.44

Loading ...

Company Profile

Company Name:
BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
11000
Office Location:
Aeschengraben 27,21st Floor,Basel,Basel-Stadt,Switzerland
Zip Code:
4051
Fax:
- -
Introduction:
BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Directors

Name
Position
John V. Oyler
Chairman of the Board,Executive Director
Michael Goller
Independent Director,Member of the Nomination Committee,Member of Other Special Committees of the Board of Directors
Ranjeev Krishana
Independent Director,Member of the Remuneration and Assessment Committee,Member of Other Special Committees of the Board of Directors
Qingqing Yi
Independent Director,Member of the Remuneration and Assessment Committee,Member of Other Special Committees of the Board of Directors
Corazon D. Sanders
Independent Director,Member of the Audit Committee,Member of Other Special Committees of the Board of Directors,Member of Other Special Committees of the Board of Directors
Margaret Dugan
Independent Director,Chairman of the Remuneration and Assessment Committee,Member of the Remuneration and Assessment Committee,Member of Other Special Committees of the Board of Directors
Alessandro Riva
Independent Director,Member of the Nomination Committee,Chairman of Other Special Committees of the Board of Directors,Member of Other Special Committees of the Board of Directors
Anthony C. Hooper
Independent Director,Chairman of the Nomination Committee,Member of the Nomination Committee,Member of the Audit Committee,Chairman of Other Special Committees of the Board of Directors,Member of Other Special Committees of the Board of Directors
Olivier Brandicourt
Independent Director,Member of the Audit Committee
Shalini Sharp
Independent Director,Member of the Nomination Committee,Chairman of the Audit Committee,Member of the Audit Committee
Xiaodong Wang
Director,Chairman of Other Special Committees of the Board of Directors,Member of Other Special Committees of the Board of Directors
ZHOU Qing Ling
Corporate Secretary
ZHOU Mi
Other Senior Executives
Lai Wang
Core Technical Personnel
Xiaobin Wu
Core Technical Personnel

Shareholders

Name
Position
John V. Oyler
CEO
Xiaobin Wu
General Manager,COO,Other Senior Executives
Chan Lee
Vice General Manager,Advisor
Aaron Rosenberg
CFO
Lai Wang
Other Senior Executives